Literature DB >> 33668052

Weight stability masks changes in body composition in colorectal cancer: a retrospective cohort study.

Justin C Brown1,2, Bette J Caan3, Elizabeth M Cespedes Feliciano3, Jingjie Xiao4, Erin Weltzien3, Carla M Prado5, Candyce H Kroenke3, Adrienne Castillo3, Marilyn L Kwan3, Jeffrey A Meyerhardt6.   

Abstract

BACKGROUND: There is an emerging viewpoint that change in body weight is not sufficiently sensitive to promptly identify clinically meaningful change in body composition, such as skeletal muscle depletion.
OBJECTIVES: We aimed to determine whether body weight stability is associated with skeletal muscle depletion and whether skeletal muscle depletion is prognostic of death independently of change in body weight.
METHODS: This retrospective cohort included 1921 patients with stage I-III colorectal cancer. Computed tomography (CT)-based skeletal muscle characteristics and body weight were measured at diagnosis and after a mean 15.0-mo follow-up. Body weight stability was defined as weight change less than ±5% during follow-up. Sarcopenia and myosteatosis were defined using established thresholds for patients with cancer. Multivariable-adjusted logistic and flexible parametric proportional hazards survival models were used to quantify statistical associations.
RESULTS: At follow-up, 1026 (53.3%) patients were weight stable. Among patients with weight stability, incident sarcopenia and myosteatosis occurred in 8.5% (95% CI: 6.3%, 10.6%) and 13.5% (95% CI: 11.1%, 15.9%), respectively. Men were more likely to be weight stable than were women (56.7% compared with 49.9%; P = 0.04). Weight-stable men were less likely to develop incident sarcopenia (5.4% compared with 15.4%; P = 0.003) and myosteatosis (9.3% compared with 20.8%; P = 0.001) than weight-stable women. Among all patients, the development of incident sarcopenia (HR: 1.40; 95% CI: 1.02, 1.91) and of myosteatosis (HR: 1.41; 95% CI: 1.05, 1.90) were associated with a higher risk of death, independently of change in body weight. Patient sex did not modify the relation between skeletal muscle depletion and death.
CONCLUSIONS: Body weight stability masks clinically meaningful skeletal muscle depletion. Body composition quantified using clinically acquired CT images may provide a vital sign to identify patients at increased risk of death. These data may inform the design of future cachexia trials.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.

Entities:  

Keywords:  cachexia; colorectal neoplasms; metabolism; myosteatosis; obesity; sarcopenia

Mesh:

Year:  2021        PMID: 33668052      PMCID: PMC8168363          DOI: 10.1093/ajcn/nqaa440

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  37 in total

1.  Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study).

Authors:  Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-15       Impact factor: 4.254

2.  Prevalence and Survival Impact of Pretreatment Cancer-Associated Weight Loss: A Tool for Guiding Early Palliative Care.

Authors:  Bhavani S Gannavarapu; Steven K M Lau; Kristen Carter; Nathan A Cannon; Ang Gao; Chul Ahn; Jeffrey J Meyer; David J Sher; Aminah Jatoi; Rodney Infante; Puneeth Iyengar
Journal:  J Oncol Pract       Date:  2018-02-21       Impact factor: 3.840

3.  Diagnostic criteria for the classification of cancer-associated weight loss.

Authors:  Lisa Martin; Pierre Senesse; Ioannis Gioulbasanis; Sami Antoun; Federico Bozzetti; Chris Deans; Florian Strasser; Lene Thoresen; R Thomas Jagoe; Martin Chasen; Kent Lundholm; Ingvar Bosaeus; Kenneth H Fearon; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

4.  Validation of clinic weights from electronic health records against standardized weight measurements in weight loss trials.

Authors:  Lan Xiao; Nan Lv; Lisa G Rosas; David Au; Jun Ma
Journal:  Obesity (Silver Spring)       Date:  2017-01-06       Impact factor: 5.002

5.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Authors:  Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

6.  Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?

Authors:  Carla M Prado; Michael B Sawyer; Sunita Ghosh; Jessica R Lieffers; Nina Esfandiari; Sami Antoun; Vickie E Baracos
Journal:  Am J Clin Nutr       Date:  2013-08-21       Impact factor: 7.045

7.  Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

Authors:  Jennifer S Temel; Amy P Abernethy; David C Currow; John Friend; Elizabeth M Duus; Ying Yan; Kenneth C Fearon
Journal:  Lancet Oncol       Date:  2016-02-20       Impact factor: 41.316

Review 8.  Measurement of skeletal muscle radiation attenuation and basis of its biological variation.

Authors:  J Aubrey; N Esfandiari; V E Baracos; F A Buteau; J Frenette; C T Putman; V C Mazurak
Journal:  Acta Physiol (Oxf)       Date:  2014-03       Impact factor: 6.311

Review 9.  Cancer-induced muscle wasting: latest findings in prevention and treatment.

Authors:  Zaira Aversa; Paola Costelli; Maurizio Muscaritoli
Journal:  Ther Adv Med Oncol       Date:  2017-03-08       Impact factor: 8.168

10.  The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS).

Authors:  Justin C Brown; Bette J Caan; Jeffrey A Meyerhardt; Erin Weltzien; Jingjie Xiao; Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Adrienne Castillo; Marilyn L Kwan; Carla M Prado
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-05-15       Impact factor: 12.910

View more
  4 in total

1.  Body composition predictors of mortality in patients undergoing surgery for long bone metastases.

Authors:  Olivier Q Groot; Michiel E R Bongers; Colleen G Buckless; Peter K Twining; Neal D Kapoor; Stein J Janssen; Joseph H Schwab; Martin Torriani; Miriam A Bredella
Journal:  J Surg Oncol       Date:  2022-01-13       Impact factor: 2.885

Review 2.  Effects of β-hydroxy β-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review.

Authors:  Carla M Prado; Camila E Orsso; Suzette L Pereira; Philip J Atherton; Nicolaas E P Deutz
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-17       Impact factor: 12.063

Review 3.  Mapping ongoing nutrition intervention trials in muscle, sarcopenia, and cachexia: a scoping review of future research.

Authors:  Camila E Orsso; Montserrat Montes-Ibarra; Merran Findlay; Barbara S van der Meij; Marian A E de van der Schueren; Francesco Landi; Alessandro Laviano; Carla M Prado
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-17       Impact factor: 12.063

4.  Prognostic value of cachexia index in patients with colorectal cancer: A retrospective study.

Authors:  Qianyi Wan; Qian Yuan; Rui Zhao; Xiaoding Shen; Yi Chen; Tao Li; Yinghan Song
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.